Share Name Share Symbol Market Type Share ISIN Share Description
Genflow Biosciences Plc LSE:GENF London Ordinary Share GB00BP2C3V08 ORD GBP0.0003
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 2.15 2.10 2.20 2.15 2.15 2.15 136,685 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology - - - - 6

Genflow Biosciences Share Discussion Threads

Showing 101 to 120 of 125 messages
Chat Pages: 5  4  3  2  1
Genflow has a wealth of transformational opportunities in the US...ho ho ho...Gla holders....2023 could be a great year for those invested in Genflow, especially from this rockbottom bargain low!!! :-)

Genflow’s focus is on the Sirtuin 6 gene, or SIRT6 for short, which is seen as ‘master regulator of healthy ageing’.

It targets four of the nine ‘hallmarks of ageing’ rather than single facets that are the preserve of other drug candidates. 

The company’s R&D effort leans very heavily into the research carried out by Dr Vera Gorbunova at the University of Rochester in the US, who is also on the company’s scientific advisory board.

or maybe a Bed & ISA given the difference in sp's.
They aren't buys they are T20 rollovers
2 x 1.9m buys!!! Looking forward to a transformational year ahead. Gla :-)
It's all good , amazing prospects and potential for transformational UPSIDE!!! Gla :-)

14 December 2022

Genflow Biosciences Plc

("Genflow" or "the Company")

Intellectual property (IP) Portfolio addition:

Patent submitted for transformational treatment of non-alcoholic fatty liver disease (NAFLD)

Genflow (LSE: GENF), would like to announce that it has filed a new patent application with the United States Patent and Trademark Office ("USPTO") that relates to variants of Sirtuin-6 ("SIRT6"), and the gene variant's therapeutic uses for the treatment of two disorders involving the liver: non-alcoholic fatty liver disease ("NAFLD"), and non-alcoholic steatohepatitis ("NASH"), an advanced form of NAFLD (the "Application").

Genflow holds the exclusive licence for this application through Genflow Biosciences SRL (the Company's Belgian subsidiary).

NAFLD affects approximately 20% of the general population, meaning this is a significant area for Genflow to be present in the research space with the potential to change the lives of many disorder sufferers. The number of people with NASH, I expected to rise dramatically in future years due to growing obesity rates in developed nations.

In the past decade, large drugmakers including Allergan, Gilead and Novartis, have spent billions of dollars acquiring or licensing medicines designed to treat NASH.

Dr Eric Leire, Founder and CEO of Genflow, said: "I'm proud of the tremendous progress Genflow has achieved in filing this new patent, and we look forward to adding to the expanding body of knowledge about ageing, liver diseases and bolstering our ever-growing patent portfolio."

IP Portfolio Update: SIRT6 Age-related cases

The international patent application for the use of SIRT6 in the treatment and prevention of age-related diseases has received its first positive review from the Patent Cooperation Treaty Examiner

The PCT Examiner has confirmed the novelty and inventiveness of Genflow's filing which represents the first significant step on the path to the patent, [for which Genflow already has an exclusive license,] being granted.

My buy of 97,500 showing as a sell!
16:52 II launches – now accepting new investors

August 22, 2022

After successful conclusion of, the second fund is now open for business. has started accepting new investors for its second fund – II; the first fund concluded with over 40+ investments, including one exit and one IPO – Genflow Bio – placing firmly in the world’s top 5 most active longevity investors.

Longevity.Technology: The fund investments fall into broad longevity categories – therapeutics and the enabling platform technologies, biomarker discovery and diagnostics, including companion diagnostics; investments also include preventative and regenerative modalities and industry accelerators. The impressive portfolio includes BrainKey, Mitrix, Pano Therapeutics, Genflow Biosciences, SENISCA, Gerostate Alpha, NOVOS and Occuity. [A full list appears at the end of this article.]

The fund aims to support and capture the innovation wave through seed, pre-seed and Series A stage investments. II will be managed by the same team led by Petr Sramek as the first fund, with newly-appointed experienced Jyothi Devakumar, PhD, as the second Managing Partner focused on science. The US-based fund operated from the firm’s Palo Alto, California office.

“The science and industry of longevity is experiencing exponential growth, and we expect massive hype after 2025 when we plan to nurture and gradually exit our portfolio companies,” said Petr Sramek. “Because longevity solutions bring real value to the global population, it will gradually become one of the largest and most impactful industries.”

The fund will start accepting new commitments from investors this week and targets the first closing of the fund in October 2022 with a target fund size of $50 million. Ongoing commitments will be accepted through the beginning of 2023 with a maximum fund size of $100 million.

Looking strong. Longevity - a great sector to be involved with. And GENF is certainly stirring into life by the looks of things:)
More results are expected from Dr Gorbunova at Rochester University for a Sirt6 Activator, not directly related to Genflow but further positive results can only add market interest and confidence. Gl :-)

Genflow’s focus is on the Sirtuin 6 gene, or SIRT6 for short, which is seen as ‘master regulator of healthy ageing’.

It targets four of the nine ‘hallmarks of ageing’ rather than single facets that are the preserve of other drug candidates. 

The company’s R&D effort leans very heavily into the research carried out by Dr Vera Gorbunova at the University of Rochester in the US, who is also on the company’s scientific advisory board.

August 2022

Gorbunova Aging Research Center team is encouraged by frailty results from SIRT6 activator trial.

SIRT6, the so-called “longevity sirtuin” has been making rather a name for itself.

SIRT6 is a protein with an important job. It is vital for both normal base excision repair and double-strand break repair of DNA damage – damage that can lead to genomic instability, which ultimately contributing to aging. These repairs decline with age but can be boosted with SIRT6 [1].

But SIRT6 has another string to its longevity bow; back in 2019, Vera Gorbunova, professor of biology at the University of Rochester, and her team, demonstrated an overexpression of SIRT6 protein leads to extended lifespan. The researchers also showed that the opposite is also true – a deficiency in SIRT6 can cause premature aging [2].


The results from the clinical trial indicate that the mice that received SIRT6Activator had significantly lower frailty scores after just a few months of treatment. Professor Gorbunova plans to issue further updates throughout the trial, and full details will be provided once the trial is completed; she hopes to publish in November of this year.

Hopefully very soon, and looking good and strong as the share price heads for 4p plus with any luck. Gla :-)
A market tiddler, under the radar, that could (and should) go ballistic
Khan says the fund is authorized to spend up to $1 billion per year indefinitely, and will be able to take financial stakes in biotech companies.

About Hevolution Foundation

Founded in the belief that every person has the right to live a longer, healthier life, Hevolution Foundation is a global catalyst, partner, and convener, on a mission to drive efforts to extend healthy human lifespan and understand the processes of aging. With a focus on aging as a treatable process,

Hevolution Foundation aims to increase the number of aging-related treatments on the market, compress the timeline of drug development, and increase accessibility to therapeutics that extend healthy lifespan, also known as healthspan.

A non-profit organization headquartered in Riyadh, with an annual budget of up to $1 Billion, Hevolution Foundation plans to open hubs in North America and other global locations to support a cutting-edge, global ecosystem of talent to propel aging and geroscience research forward and achieve medical breakthroughs to help humanity live healthier, longer.

Saudi Arabia plans to spend $1 billion a year discovering treatments to slow aging

June 7, 2022

Anyone who has more money than they know what to do with eventually tries to cure aging. Google founder Larry Page has tried it. Jeff Bezos has tried it. Tech billionaires Larry Ellison and Peter Thiel have tried it.

Now the kingdom of Saudi Arabia, which has about as much money as all of them put together, is going to try it.

The Saudi royal family has started a not-for-profit organization called the Hevolution Foundation that plans to spend up to $1 billion a year of its oil wealth supporting basic research on the biology of aging and finding ways to extend the number of years people live in good health, a concept known as “health span.”

The sum, if the Saudis can spend it, could make the Gulf state the largest single sponsor of researchers attempting to understand the underlying causes of aging—and how it might be slowed down with drugs.

The foundation hasn’t yet made a formal announcement, but the scope of its effort has been outlined at scientific meetings and is the subject of excited chatter among aging researchers, who hope it will underwrite large human studies of potential anti-aging drugs.

The fund is managed by Mehmood Khan, a former Mayo Clinic endocrinologist and the onetime chief scientist at PespsiCo, who was recruited to the CEO job in 2020. ““Our primary goal is to extend the period of healthy life span,” Khan said in an interview. "There is not a bigger medical problem on the planet than this one.”


“We need to translate that biology to progress toward human clinical research. Ultimately, it won’t make a difference until something appears in the market that actually benefits patients,” Khan says.

Khan says the fund is authorized to spend up to $1 billion per year indefinitely, and will be able to take financial stakes in biotech companies. By comparison, the division of the US National Institute on Aging that supports basic research on the biology of aging spends about $325 million a year.

Hevolution hasn’t announced what projects it will back, but people familiar with the group say it looked at funding a $100 million X Prize for age reversal technology and has reached a preliminary agreement to fund a test of the diabetes drug metformin in several thousand elderly people.

Cheers felch, cheaps as chips, considering Genflow's potential and prospects in an area that is attracting so much investment, a bargain share price and lowly market cap which could explode Northwards at anytime, in the meantime upward momentum as the re-rate continues...a very exciting stock to hold imho Gl :-)
Another great find, moneymunch. It's great to still be able to invest in this stock at such an incredibly low price.
Scientists make big breakthroughs in unravelling the secret to reversing ageing

Experts say that it is easily possible to extend human life expectancy to way beyond current levels, a concept helped by billionaires pumping huge volumes of cash into the industry.

Kristen Fortney, CEO of San Francisco-based BioAge Labs, told Sky News: "There's no hard limits imposed by biology or by physics that says that we can't live better longer." And this is an area of scientific research that some of the world's richest entrepreneurs are taking an interest in.

Amazon founder Jeff Bezos, for instance, provided anti-ageing start-up Altos Labs with a huge $3billion (£2.5billion) cash injection.  And, this is not Mr Bezos' first venture into the anti-ageing domain either. 

The billionaire has also pumped cash into California-based firm UNITY Biotechnology, a start-up searching for therapies to slow or reverse the symptoms of ageing, with PayPal co-founder Peter Thiel also investing in the firm. According to a report by P&S Intelligence, the global anti-ageing market is predicted to skyrocket from around $191.5billion (£160billion) at current levels to a staggering $421.4billion (£352billion) by 2030. 

Due to the huge funding the industry is receiving, it is perhaps no wonder that exciting breakthroughs in the field are being found more regularly. 

Chat Pages: 5  4  3  2  1
Your Recent History
Genflow Bi..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20230207 14:07:25